Jesús F. San Miguel-rekin lankidetzan egindako argitalpenak (8)

2017

  1. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone

    Haematologica, Vol. 102, Núm. 1, pp. 168-175

2016

  1. Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma

    American Journal of Pathology, Vol. 186, Núm. 8, pp. 2171-2182

1999

  1. Immunoglobulin lambda chain gene rearrangement in a case of acute nonlymphoblastic leukemia [3]

    Leukemia

1998

  1. TCR-gamma gene rearrangement with interstitial deletion within the TRGV2 gene segment is not detected in normal T-lymphocytes

    Leukemia

1993

  1. Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: Phenotypic and genomic differences

    American Journal of Hematology, Vol. 43, Núm. 4, pp. 256-258

1992

  1. Immunophenotype in erythroleukemia secondary to myelodysplastic syndrome [3]

    Blood

1991

  1. Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia

    British Journal of Haematology, Vol. 79, Núm. 3, pp. 408-414